Sinaptica Therapeutics (#LSIAlumni) is developing a totally new way of treating Alzheimer's disease with a drug free, noninvasive, neuromodulation approach. During this #LSIEurope23 interview, Ken Mariash, CEO of Sinaptica Therapeutics, provides an update on the company’s recent developments and shares a glimpse of what we can anticipate in 2024 and beyond. Sinaptica’s positive Phase II trial results published in October 2022, showed an unprecedented reduction in cognitive decline and improved function in mild-to-moderate Alzheimer’s disease patients. The results showed greater than 80% disease slowing on all four gold-standard cognitive and functional endpoints. What’s next for Sinaptica Therapeutics? They’re full steam ahead towards their pivotal trial. You can watch the rest of this interview with Ken Mariash, and a second interview with Sinaptica Co-Founder and Scientific Advisor, Emiliano Santarnecchi, on our website and YouTube channel. 🔗 Full Interview with Ken Mariash: https://lnkd.in/g-qNgk42 🔗 Full Interview with Emiliano Santarnecchi: https://lnkd.in/gGNNJeED
So exciting Ken Mariash !
Chief Commercial Officer @ Oxford Brain Diagnostics | Healthcare Technology
9mosome amazing insights LSI.....and cannot wait to see Sinaptica Therapeutics go to the next stage.